Kelly Michael Aaron 4

What Happened
Kelly Michael Aaron, a director of Prime Medicine (PRME), was granted a derivative award covering 75,000 shares on June 5, 2026. The Form 4 lists an acquisition price of $0.00 (no cash exchanged). This was a grant/award (not a sale or open-market purchase).

Key Details

• Transaction date: 2026-06-05; Form 4 filed: 2026-06-08 (timely filed).
• Transaction type: Award/derivative (code A); 75,000 shares acquired at $0.00.
• Shares owned after transaction: Not specified in the provided filing.
• Vesting note (F1): The award vests in full on the earlier of (i) June 5, 2027 or (ii) the date of the next annual meeting of stockholders, subject to continuous service.
• No 10b5‑1 plan, tax‑withholding sale, or exercise/sale indicated in this filing.

Context
This was a compensation-style derivative grant (e.g., options or RSUs structured as a derivative award) rather than a market purchase or sale. Because the award vests in the future and no cash changed hands, it does not represent an immediate change in market holdings or a realized gain/loss. Awards like this are commonly part of director compensation and should be viewed as such rather than a direct trading signal.